Policy Briefs on THE

ECONOMIC IMPACT OF HIV

Impact of HIV

Brief 2: Increased Health and Life Prospects and Their Economic Valuation

By Markus Haacker, Kate Harris, Gesine Meyer-Rath, Lisa Robinson

August 2021

Key Points

  • Antiretroviral therapy has dramatically improved the life prospects of people living with HIV.
  • Reduced AIDS-related mortality has been a dominant driver of improvements in life expectancy across sub-Saharan Africa and has made important contributions even in countries facing relatively low HIV prevalence.

 

  • The principal economic gains arise from improved survival through higher lifetime earnings and the perceived value of longer lives, but some of these economic gains cannot be used directly for offsetting costs of health investments.
Download PDF HIV Impact

Technical Briefs

The technical briefs provide more detail on the evidence available on each of the topics.

1. The State of Programme Implementation to Reduce HIV Transmission & Aids-Related Mortality

2. Increased Health and Life Prospects and Their Economic Valuation

3. HIV, Population Dynamics and the Labour Force

4. Human Capital

5. Capital and Investment

6. Productivity and Employment of People Living with HIV

7. Economic Growth – Overview

8. Interactions Between HIV and Poverty

9. Disease Burden Across Population Sub-Groups

10. Trade-offs between Allocation to Health and Other Sectors

11. Domestic Public Funding for HIV

12. Trade-offs and Synergies between HIV and Other Health Objectives

13. Assessing Cost Effectiveness Across HIV and Health Interventions

14. External and Domestic Health Financing, and the Role of Public vs. Private Domestic Health Funding

15. Public and Private Provision of Health and HIV Services

16. Trade-offs within the HIV Budget

17. The Economics of HIV and of HIV Programmes in the Era of Covid-19

Brief 2: Increased Health and Life Prospects and Their Economic Valuation

By Markus Haacker, Kate Harris, Gesine Meyer-Rath, Lisa Robinson

August 2021

Key Points

  • Antiretroviral therapy has dramatically improved the life prospects of people living with HIV.
  • Reduced AIDS-related mortality has been a dominant driver of improvements in life expectancy across sub-Saharan Africa and has made important contributions even in countries facing relatively low HIV prevalence.

 

  • The principal economic gains arise from improved survival through higher lifetime earnings and the perceived value of longer lives, but some of these economic gains cannot be used directly for offsetting costs of health investments.
Download PDF HIV Impact

Technical Briefs

The technical briefs provide more detail on the evidence available on each of the topics.

1. The State of Programme Implementation to Reduce HIV Transmission & Aids-Related Mortality

2. Increased Health and Life Prospects and Their Economic Valuation

3. HIV, Population Dynamics and the Labour Force

4. Human Capital

5. Capital and Investment

6. Productivity and Employment of People Living with HIV

7. Economic Growth – Overview

8. Interactions Between HIV and Poverty

9. Disease Burden Across Population Sub-Groups

10. Trade-offs between Allocation to Health and Other Sectors

11. Domestic Public Funding for HIV

12. Trade-offs and Synergies between HIV and Other Health Objectives

13. Assessing Cost Effectiveness Across HIV and Health Interventions

14. External and Domestic Health Financing, and the Role of Public vs. Private Domestic Health Funding

15. Public and Private Provision of Health and HIV Services

16. Trade-offs within the HIV Budget

17. The Economics of HIV and of HIV Programmes in the Era of Covid-19

Wits Health Consortium, University of the Witwatersrand